EUVIMEDEUVIMED entdecken
Open Access

Chitosan‐Functionalized Liposome‐Mediated Fundus Delivery of Epigallocatechin‐3‐Gallate for Diabetic Retinopathy Therapy

Xingxiu Jiang, Haoliang Shi, Binbin Chu, Yulan Gu, Yicheng Zhang, Li Wang, Yao He, Xiaofeng Zhang iD

Advanced Healthcare Materials · 2026-07 · 15 (27)

DOI: 10.1002/adhm.202505083 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 12.06.2026. Verfasst von Xingxiu Jiang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Catechin, Liposomes, Chitosan, Diabetic Retinopathy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Science and Technology Project of Suzhou Municipal Health Commission, Suzhou Science and Technology Plan Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Among working‐age adults in the contemporary era, more than 30% of individuals with diabetes are at risk of developing diabetic retinopathy (DR), a progressive ocular disorder that is the leading cause of visual impairment and blindness. Despite its high prevalence, treatment options remain limited. Current therapeutic strategies only focus on the inhibition of neovascularization or prevention of vascular leakage. Additionally, the majority of conventional eye drop formulations fail to deliver drugs efficiently to the retina, further limiting clinical applicability. To address these issues, we herein designed and developed an eye drop formulation based on the chitosan‐modified liposomes encapsulating epigallocatechin‐3‐gallate (EGCG), capable of transporting EGCG from the ocular surface to the retina. Mechanistic studies revealed that efficient retinal delivery of EGCG could protect Müller cells against high glucose (HG)‐induced injury via SIRT1‐BNIP3‐mediated mitophagy. In vivo, the developed EGCG@CS‐LIP showed enhanced fundus delivery and therapeutic efficacy compared with conventional liposomes or free EGCG systems, attributed to the transient modulation of corneal tight junctions. More importantly, the EGCG@CS‐LIP eye drops could effectively increase the expression level of SIRT1 protein and inhibit the apoptosis and damage in retina, thus exerting significant in vivo therapeutic effects for the effective treatments of DR. Lastly, the constructed EGCG@CS‐LIP indicated the excellent ocular biocompatibility, highlighting its promise for future clinical translation in DR therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CatechinLiposomesChitosanDiabetic RetinopathyAnimalsMiceHumansRetinaSirtuin 1Ophthalmic SolutionsMice, Inbred C57BL

Stichwörter der Autor:innen

EGCGdiabetic retinopathyeyedropsfundus deliveryliposomesmitophagy

Substanzen

Catechinepigallocatechin gallateLiposomesChitosanSirtuin 1Ophthalmic Solutions

Autor:innen und Institutionen

  • Department of Ophthalmology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China.
  • Suzhou Key Laboratory of Nanotechnology and Biomedicine, Institute of Functional Nano & Soft Materials & Collaborative Innovation Center of Suzhou Nano Science and Technology (NANO-CIC), Soochow University, Suzhou, Chin…
  • Institute for NanoBioTechnology, Johns Hopkins University, Baltimore, Maryland, USA.
  • Translational Tissue Engineering Center, Johns Hopkins University, Baltimore, Maryland, USA.
  • Macao Translational Medicine Center, Macau University of Science and Technology, Taipa, Macau SAR, China.
  • Macao Institute of Materials Science and Engineering, Macau University of Science and Technology, Taipa, Macau SAR, China.

ORCID-Profile: Xiaofeng Zhang

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Project of Suzhou Municipal Health Commission
  • Suzhou Science and Technology Plan Project
  • Gusu Health Talent Program Talent Research Project
  • Science and Technology Development Fund, Macau SAR
  • National Key R&D Program of China
  • Priority Academic Program Development of Jiangsu Higher Education Institutions
  • 111 Project

Zitieren

APA

Jiang, X., Shi, H., Chu, B., Gu, Y., Zhang, Y., Wang, L., He, Y., & Zhang, X. (2026). Chitosan‐Functionalized Liposome‐Mediated Fundus Delivery of Epigallocatechin‐3‐Gallate for Diabetic Retinopathy Therapy. Advanced Healthcare Materials, 15(27). https://doi.org/10.1002/adhm.202505083

Vancouver

Jiang X, Shi H, Chu B, Gu Y, Zhang Y, Wang L, et al. Chitosan‐Functionalized Liposome‐Mediated Fundus Delivery of Epigallocatechin‐3‐Gallate for Diabetic Retinopathy Therapy. Advanced Healthcare Materials. 2026;15(27). doi:10.1002/adhm.202505083

BibTeX
@article{Jiang2026,
  author = {Jiang, Xingxiu and Shi, Haoliang and Chu, Binbin and Gu, Yulan and Zhang, Yicheng and Wang, Li and He, Yao and Zhang, Xiaofeng},
  title = {Chitosan‐Functionalized Liposome‐Mediated Fundus Delivery of Epigallocatechin‐3‐Gallate for Diabetic Retinopathy Therapy},
  journal = {Advanced Healthcare Materials},
  year = {2026},
  volume = {15},
  number = {27},
  doi = {10.1002/adhm.202505083}
}
Kostenlos starten →